- Home
- SKYE vs USIO Comparison
SKYE vs USIO Comparison
Compare SKYE & USIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- USIO
- Stock Information
- Founded
- SKYE 2012
- USIO 1998
- Country
- SKYE United States
- USIO United States
- Employees
- SKYE N/A
- USIO N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- USIO Investment Bankers/Brokers/Service
- Sector
- SKYE Health Care
- USIO Finance
- Exchange
- SKYE Nasdaq
- USIO Nasdaq
- Market Cap
- SKYE 46.5M
- USIO 37.6M
- IPO Year
- SKYE N/A
- USIO N/A
- Fundamental
- Price
- SKYE $1.46
- USIO $1.46
- Analyst Decision
- SKYE Strong Buy
- USIO Strong Buy
- Analyst Count
- SKYE 5
- USIO 1
- Target Price
- SKYE $14.75
- USIO $4.00
- AVG Volume (30 Days)
- SKYE 456.9K
- USIO 55.1K
- Earning Date
- SKYE 11-10-2025
- USIO 11-12-2025
- Dividend Yield
- SKYE N/A
- USIO N/A
- EPS Growth
- SKYE N/A
- USIO N/A
- EPS
- SKYE N/A
- USIO 0.11
- Revenue
- SKYE N/A
- USIO $83,851,606.00
- Revenue This Year
- SKYE N/A
- USIO $8.71
- Revenue Next Year
- SKYE N/A
- USIO $12.48
- P/E Ratio
- SKYE N/A
- USIO $13.65
- Revenue Growth
- SKYE N/A
- USIO 2.05
- 52 Week Low
- SKYE $1.14
- USIO $1.24
- 52 Week High
- SKYE $5.90
- USIO $2.92
- Technical
- Relative Strength Index (RSI)
- SKYE 37.63
- USIO 53.44
- Support Level
- SKYE $1.42
- USIO $1.43
- Resistance Level
- SKYE $1.60
- USIO $1.52
- Average True Range (ATR)
- SKYE 0.10
- USIO 0.05
- MACD
- SKYE 0.08
- USIO 0.00
- Stochastic Oscillator
- SKYE 34.63
- USIO 69.23
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.